source
- Jazz's Ziihera receives FDA approval for first-line treatment of HER2-positive gastroesophageal cancerThe U.S. Food and Drug Administration has approved Jazz Pharmaceuticals' bispecific antibody Ziihera for use as a first‑line therapy in patients with unresectable locally advanced or metastatic gas…
- Akeso and Summit report ivonescimab meets primary endpoint in China Phase 3 biliary tract cancer trialAkeso Therapeutics and partner Summit Therapeutics announced that their bispecific antibody ivonescimab achieved the primary efficacy endpoint in a Phase 3 study conducted exclusively in China. Th…